The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies
Abstract
This last decade has been marked by significant advances in the development of cell and gene (C&G) therapies, such as gene targeting or stem cell-based therapies. C&G therapies offer transformative benefits to patients but present a challenge to current health technology decision-making systems because they are typically reviewed when clinical efficacy data are very limited and when there is uncertainty about the long-term durability of outcomes. These challenges are not unique to C&G therapies, but they face more of these barriers, reflecting the need for adapting existing value assessment frameworks. Still, C&G therapies have the potential to be cost-effective even at very high price points. The impact on healthcare budgets will depend on the success rate of pipeline assets and on the extent to which C&G therapies will expand to wider pathologies beyond rare or ultra-rare diseases. Getting pricing and reimbursement models right is important for incentivising research and development investment while not jeopardising the sustainability of healthcare systems. Payers and manufacturers therefore need to acknowledge each other's constraints-limitations in the evidence generation on the manufacturer side, budget considerations on the payer side-and embrace innovative thinking and approaches to ensure timely delivery of therapies to patients. Several experts in health technology assessment and clinical experts have worked together to produce this publication and identify methodological and policy options to improve the assessment of C&G therapies, and make it happen better, faster and sustainably in the coming years.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and is further complicated by high levels of uncertainty, owing to the lack of data regarding safety (potential adverse events resulting from the delivery procedure and long-term side effects) and effectiveness, as well as suitable comparators for several conditions typically targeted by ATMPs.”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [78]
In the citing paper
“Assessing the cost-effectiveness and economic value of ATMPs is complex [20, 77, 78]”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [78]
Citations
Cites
Austin, P. C. (2011) · Multivariate Behavioral Research · doi:10.1080/00273171.2011.568786 · Cited by 12,242
Sanders, G. D., Neumann, P. J., Basu, A., Brock, D. W., Feeny, D., Krahn, M., Kuntz, K. M., Meltzer, D. O., Owens, D. K., Prosser, L. A., et al. (2016) · JAMA · doi:10.1001/jama.2016.12195 · Cited by 3,069
Jansen, J. P., Fleurence, R., Devine, B., Itzler, R., Barrett, A., Hawkins, N., Lee, K., Boersma, C., Annemans, L., & Cappelleri, J. C. (2011) · Value in Health · doi:10.1016/j.jval.2011.04.002 · Cited by 1,036
Hoaglin, D. C., Hawkins, N., Jansen, J. P., Scott, D. A., Itzler, R., Cappelleri, J. C., Boersma, C., Thompson, D., Larholt, K. M., Diaz, M., et al. (2011) · Value in Health · doi:10.1016/j.jval.2011.01.011 · Cited by 770
Demystifying trial networks and network meta-analysis
Mills, E. J., Thorlund, K., & Ioannidis, J. P. A. (2013) · BMJ · doi:10.1136/bmj.f2914 · Cited by 742
Lakdawalla, D. N., Doshi, J. A., Garrison, L. P., Phelps, C. E., Basu, A., & Danzon, P. M. (2018) · Value in Health · doi:10.1016/j.jval.2017.12.007 · Cited by 540
Self-citationObservational study of spinal muscular atrophy type I and implications for clinical trials
Finkel, R. S., McDermott, M. P., Kaufmann, P., Darras, B. T., Chung, W. K., Sproule, D. M., Kang, P. B., Foley, A. R., Yang, M. L., Martens, W. B., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000741 · Cited by 528
Self-citationMethods for Population-Adjusted Indirect Comparisons in Health Technology Appraisal
Phillippo, D. M., Ades, A. E., Dias, S., Palmer, S., Abrams, K. R., & Welton, N. J. (2018) · Medical Decision Making · doi:10.1177/0272989x17725740 · Cited by 396
Self-citationGarrison, L. P., Towse, A., Briggs, A., de Pouvourville, G., Grueger, J., Mohr, P. E., Severens, J. L. (., Siviero, P., & Sleeper, M. (2013) · Value in Health · doi:10.1016/j.jval.2013.04.011 · Cited by 314
Self-citationNICE Guide to the Methods of Technology Appraisal: Pharmaceutical Industry Perspective
Earnshaw, J., & Lewis, G. (2008) · PharmacoEconomics · doi:10.2165/00019053-200826090-00002 · Cited by 226
Research works printed but not linked: 2
- Food & Drug Administration: Fast track, breakthrough therapy, accelerated approval, priority review, (2018a)
- NICE: Guide to the Methods of Technology Appraisal. NICE, London (2013)
Cited by
Zhang, M., Bao, Y., Lang, Y., Fu, S., Kimber, M., Levine, M., & Xie, F. (2021) · Value in Health · doi:10.1016/j.jval.2021.07.005 · Cited by 64
Real World Data in Health Technology Assessment of Complex Health Technologies
Milou, M., Pontén, J., Vreman, R. A., Mantel-Teeuwisse, A. K., & Goettsch, W. G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.837302 · Cited by 62
“Often there is uncertainty around long-term claims for gene-therapies and other ATMPs as clinical trials do not cover life-long effects (Fruergaard Jorgensen, 2017; Jönsson et al., 2019; Coyle et al., 2020).”
BackgroundFacey, K. M., Espín, J., Kent, E., Link, A., Nicod, E., O’Leary, A. C., Xoxi, E., van de Vijver, I., Zaremba, A., Benisheva, T., et al. (2021) · PharmacoEconomics · doi:10.1007/s40273-021-01050-5 · Cited by 54
Rare Disease, Advocacy and Justice: Intersecting Disparities in Research and Clinical Care
Halley, M. C., Halverson, C. M. E., Tabor, H. K., & Goldenberg, A. J. (2023) · The American Journal of Bioethics · doi:10.1080/15265161.2023.2207500 · Cited by 56
“CASE 1: THE PARADOX OF NEWBORN SCREENING DISPARITIES Newborn screening (NBS) is frequently used as an example of a public health program in which health disparities do not exist.”
BackgroundInfluentialDrummond, M., Ciani, O., Fornaro, G. A., Jommi, C., Dietrich, E. S., Espín, J., Mossman, J., & de Pouvourville, G. (2023) · BMC Health Services Research · doi:10.1186/s12913-023-09494-5 · Cited by 43
“Several of the papers reviewed stressed the importance of managed entry, or market access agreements for cell and gene therapies, either because of the high cost of these products and/or the uncertainty over their clinical effectiveness [4, 6].”
Background
Metadata
- Authors
- Coyle, D., Durand-Zaleski, I., Farrington, J., Garrison, L., Graf von der Schulenburg, J.-M., Greiner, W., Longworth, L., Meunier, A., Moutié, A.-S., Palmer, S., Pemberton-Whiteley, Z., Ratcliffe, M., Shen, J., Sproule, D., Zhao, K., & Shah, K.
- Affiliations
- University of Ottawa (CA)
- University of Washington (US)
- Bielefeld University (DE)
- University of York (GB)
- Novartis (Switzerland) (CH)
- China National Health Development Research Center (CN)
- Corresponding author
- Moutié, Anne-Sophie
- ORCID
- Venue
- The European Journal of Health Economics
- Published
- 2020-08-13
- Volume
- 21
- Issue
- 9
- Pages
- 1421-1437
- ISSN
- 1439-3972 (ISSN-L)
- 1618-7598
- 1618-7601
- OpenAlex
- W3049322734
- Cited by
- 71
- References
- 50
- Citations by year
- 2026: 11 · 2025: 4 · 2024: 21 · 2023: 8 · 2022: 11 · 2021: 16
- FWCI
- 7.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- The European Journal of Health Economics (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- PUB – Publications at Bielefeld University (Bielefeld University) (submittedVersion)
- Funders
- Novartis Pharma
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
- Keywords
- cell and gene therapy, health technology assessment, value assessment framework, cost-effectiveness, pricing and reimbursement, health policy, evidence gaps, rare diseases, stem cell therapy, gene targeting
- MeSH terms
- Cost-Benefit Analysis, Humans, Policy Making, Technology Assessment, Biomedical, Genetic Therapy, Rare Diseases, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies. https://app.cochat.ai/papers/10.1007/s10198-020-01212-w
- The paper
- Coyle, D., Durand-Zaleski, I., Farrington, J., Garrison, L., Graf von der Schulenburg, J.-M., Greiner, W., Longworth, L., Meunier, A., Moutié, A.-S., Palmer, S., Pemberton-Whiteley, Z., Ratcliffe, M., Shen, J., Sproule, D., Zhao, K., & Shah, K. (2020). HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies. The European Journal of Health Economics. https://doi.org/10.1007/s10198-020-01212-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.